---
title: "BPC-157 Legal Status in 2026"
url: "https://nexteralegal.com/blog/is-bpc-157-legal/"
description: "Where BPC-157 stands after the Category 2 removal and the PCAC 8-6 vote, and what compounding pharmacies and peptide clinics may legally do now."
author: "Eric Proos"
published: "2026-08-04T19:55:39+00:00"
updated: "2026-11-09T01:11:29.283364+00:00"
publisher: "Next Era Legal"
---

Resources · Peptide product risks

# Is BPC-157 legal in 2026?

Where BPC-157 stands after its removal from Category 2 and the July 2026 advisory committee vote, and what pharmacies and clinics can do now.

01 The short answer

## Legal to study, unsettled to prescribe.

BPC-157 is **not an FDA-approved drug** and its removal from the bulk-substances category it had been considered under narrowed how it can lawfully be compounded. What a pharmacy, clinic or supplier may do now turns on sourcing, the compounding pathway relied on, and state board rules. This page tracks that position.

Updated 9 November 2026 Peptide therapy Status as the source states it

- **FDA-approved:** No For any indication
- **Category 2:** Removed April 22, 2026
- **PCAC vote:** 8-6 to add July 23-24, 2026, advisory
- **503A Bulks List:** Not on it Rulemaking not finished

02 Where it stands

## It depends on what you do with it.

The position is unsettled. This page describes the status **as of July 2026**, as our source states it; check the current position before relying on it.

- BPC-157 is not FDA-approved for any indication, and there is no commercially available prescription product.
- The FDA has removed it from the Category 2 list.
- An FDA advisory committee has recommended adding it to the 503A Bulks List, but the rulemaking is not finished, so it is not on that list.
- Buying, possessing and using it for legitimate research remains legal.
- Prescribing, compounding and administering it to patients sits in a regulatory gap.

03 The peptide

## One peptide, three legal frameworks.

BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein found in human gastric juice. It has been studied in animal models for tissue repair, wound healing, gut mucosal protection and inflammatory modulation. The clinical interest behind its nomination for FDA review is mainly Ulcerative Colitis, though regenerative and sports medicine providers have used it more broadly.

Three legal frameworks meet here: FDA drug approval, compounding pharmacy law under Section 503A of the Federal Food, Drug, and Cosmetic Act, and state medical practice rules. A provider's exposure depends on which one applies and on how the peptide is sourced, prescribed and administered. It has no completed human clinical trials, so every clinical use sits outside the normal drug approval path, and whether it is lawful depends on whether the compounding and prescribing route meets federal and state requirements.

04 The timeline

## Four steps, none of them final.

How BPC-157's regulatory status has changed, as the source states it

| When | What happened | What it did |
| --- | --- | --- |
| Late 2023 | The FDA placed BPC-157 on its Category 2 list of bulk drug substances under 503A | Closed the compounding pathway for individual patient prescriptions |
| February 27, 2026 | HHS Secretary Robert F. Kennedy Jr. announced that about 14 of the 19 restricted peptides, BPC-157 included, would be considered for reclassification from Category 2 to Category 1 | A policy direction only; it changed no legal status |
| April 22, 2026 | The FDA formally removed BPC-157 from Category 2 | Removed a barrier, but did not authorize compounding |
| July 23-24, 2026 | The Pharmacy Compounding Advisory Committee (PCAC) met at the FDA White Oak Campus | Voted 8-6 to recommend adding BPC-157 to the 503A positive Bulks List; the recommendation is advisory |

05 Category 2

## A barrier removed, no permission granted.

### What the Category 2 designation prohibited

Category 2 covers substances the FDA flagged as raising significant safety concerns, including immunogenicity, peptide-related impurities and thin safety data. Once BPC-157 was listed, licensed 503A compounding pharmacies could no longer lawfully compound it for individual patients on a physician's prescription. The 503A Bulks List is the only route for a pharmacy to prepare a substance that is not a component of an FDA-approved drug and has no USP monograph, and that route closed.

It did not make BPC-157 illegal to possess or study, and it stayed available as Research Use Only (RUO). The trouble came from the line between research and clinical use. The FDA treats prescribing, reconstituting or administering RUO peptides to humans as misbranding and distributing unapproved new drugs. More than 50 warning letters to compounders, online sellers and clinics rest on that view.

05 Category 2 · continued

### What removal changes, and what it does not

Removal ended the FDA's formal designation of BPC-157 as a substance with significant safety concerns for compounding. It is not the same as being added to the Category 1 Bulks List, and it does not affirmatively authorize compounding.

To be lawfully compounded under Section 503A, a substance must be a component of an FDA-approved drug, have a USP monograph, or be on the 503A positive Bulks List. After the removal, BPC-157 met none of the three. Some pharmacies resumed compounding it on the theory that removing the negative designation, plus the advisory committee review, gave enough cover. Whether the FDA will accept that theory is not yet known. The February announcement was likewise a policy direction, not a regulatory action, and providers who treated it as permission to compound or prescribe faced enforcement.

06 The PCAC vote

## A recommendation, not a rule.

The committee reviewed BPC-157 with six other peptides: TB-500, KPV, MOTS-c, Semax, Epitalon and DSIP. It voted 8-6 to recommend adding BPC-157 to the 503A positive Bulks List. Six of the seven peptides got favorable recommendations; only DSIP was rejected. The vote ran against the FDA's own briefing documents, which had recommended against adding any of the seven.

A positive recommendation is advisory. It is not FDA approval and it does not authorize compounding. It starts a formal rulemaking process: a Notice of Proposed Rulemaking, a public comment period and a final rule, which the source says typically takes additional months. Until a final rule is published, BPC-157 is not on the 503A Bulks List and the compounding pathway is incomplete.

07 Risk and response

## Enforcement is active; prepare, do not jump.

### The enforcement risk providers face now

The FDA issued more than 50 warning letters to peptide sellers, compounding pharmacies and clinics between late 2024 and mid-2026. Sweeps in March and April 2026 targeted online sellers whose RUO-labeled peptides came with marketing that suggested human use, disease treatment claims or wellness benefits, including seven letters in April alone. An RUO disclaimer gives no cover when the marketing, packaging or distribution channel shows the product is meant for people.

The source also reports that the Department of Justice has signaled federal criminal charges are being prepared against certain industry participants, that Ohio's medical and pharmacy boards have opened investigations into clinics dispensing non-FDA-approved peptides from unlicensed suppliers, and that California is reviewing clinics that prescribed Category 2 substances during the restriction period. State medical boards can suspend or revoke a medical license, and their standard of proof is lower than in a criminal case.

07 Risk and response · continued

### What providers and clinics should do now

- **Source.** If BPC-157 is added to the 503A Bulks List, lawful compounding will require a licensed 503A pharmacy meeting USP 797 standards. Until then, any clinical source operates outside the established framework. Do not buy from overseas manufacturers, online RUO vendors or any supplier that is not an FDA-registered facility.
- **Prescribe and document.** Every prescription needs a valid patient-specific prescription from a licensed provider, documented medical necessity, informed consent, and ongoing monitoring with recorded outcomes. Consent should be written, signed and kept in the record, and state the peptide, source, lot number, route, dosage, expected benefits and known risks, including its non-FDA-approved status.
- **Check your structure.** Your ownership and operations must comply with corporate practice of medicine laws in your state. If you use a Management Services Organization, procurement of pharmaceutical products stays under the physician's direct control, and clinical protocols are documented as the physician's independent judgment.
- **Prepare, do not jump.** Line up licensed 503A pharmacy relationships, compliant consent documents and record-keeping now, so the practice is ready if a final rule is published. The broader checklist is on our [peptide clinic compliance](https://nexteralegal.com/who-we-serve/peptide-and-wellness/) page.

08 When this needs a lawyer

## Before you source, prescribe or answer a letter.

- **You are choosing or changing where your clinic obtains BPC-157** — sourcing decides most of the exposure.
- **A pharmacy has told you it is compounding BPC-157** — you need to judge the risk of the theory it relies on.
- **You are drafting informed consent or documentation for peptide therapy** — the record is what a board or regulator reads first.
- **Your clinic uses an MSO and you are unsure the structure would hold up to review** — corporate practice of medicine rules apply.
- **You have received a warning letter or a state board inquiry** — bring in a regulatory attorney now. We serve as [fractional general counsel for highly regulated businesses](https://nexteralegal.com/who-we-serve/highly-regulated-industries/), including peptide therapy clinics and compounding pharmacies.

**This is general information, not legal advice.** It describes a regulatory position as our source stated it in July 2026, which may since have changed, and cannot account for your clinic, your facts or your state. Reading it does not create an attorney–client relationship.

**[Eric Proos](https://nexteralegal.com/about/eric-proos/)** Founding Partner · Corporate & Commercial Real Estate

## Peptide Product Risks.

1. [1 SAFE vs Convertible Note](https://nexteralegal.com/blog/safe-vs-convertible-note/)
2. [2 Trade Secrets vs Patents](https://nexteralegal.com/blog/trade-secret-vs-patent/)
3. [3 HVAC & Home Service Pitfalls](https://nexteralegal.com/blog/hvac-maintenance-contracts/)
4. *4* Peptide Product Risks

[Next: Case Studies: Case Study Hub How growth-stage companies handled a raise, an acquisition, a restructure and a compliance problem - what was at stake and what actually changed.](https://nexteralegal.com/case-studies/)

Case study

## From nothing on paper to built for venture funding.

No structure, no IP protection, no legal operations strategy. Find out what a technology platform put in place first, with venture funding as the goal.

[Or download the two-page PDF](https://nexteralegal.com/obs/assets/img/cases/sheets/compliance-from-day-one.pdf)

Free guide

## How to buy or sell commercial property with an edge at the table.

Know exactly what is changing hands before you commit. Manage diligence and the key approvals, shift risk where you can, limit what follows you after the deal, and close with control.

Free. Sent to your email.

Free checklist

## How to pick the right seed instrument before you raise.

Know your dilution before you sign. Compare convertible notes, SAFEs, Series Seed preferred and common stock side by side, and see what each one costs you in interest, caps and conversion terms.

Free. Sent to your email.

1. [Case study: see all 9 case studies](https://nexteralegal.com/case-studies/#cases)
2. [Guide: see all 7 guides](https://nexteralegal.com/guides/#all-guides)
3. [Checklist: see all 4 checklists](https://nexteralegal.com/checklists/#checklists)

In clients’ words

## What clients say.

Five stars Google

> “I hired Next Era Legal to assist with my law firm's corporate incorporation and state bar application, and I couldn't be more pleased with the experience. They completed all paperwork promptly and accurately, and their communication…”

— **Sally Reddy** San Diego Review

Five stars Google

> “can't recommend Eric and his team highly enough! As a small business owner, I had a lot of questions and concerns, and Eric was incredibly knowledgeable, patient, and thorough every step of the way. He helped me feel confident navigating…”

— **Chelsea Wolfe** Los Angeles Review

Five stars Google

> “I have known Atty Jeff Monahan through a professional networking group. He is extremely knowledgeable and easy to talk to. I have consulted with him in several occasions regarding my businesses and I have known several other people who have consulted with him and rave about him as well. I highly recommend his services.”

— **Shohreh Janfaza** Los Angeles Review

Five stars Google

> “Next Era Legal is the kind of law firm every business owner wishes they had. They actually understand how businesses operate and don't just give legal advice; they provide real, strategic guidance that helps move deals forward. Working with…”

— **Victor Mendoza** Los Angeles Review

Five stars Google

> “Fantastic lawyer, Eric gave us Incredible service from start to finish, was professional, efficient, and always available to answer my questions. I felt supported and informed every step of the way. Highly recommended!”

— **Riccardo Vincenzi** Los Angeles Review

Five stars Google

> “Eric and his team have been fantastic partners to both myself and my clients. They are personable and cost efficient, which is exactly what I was looking for. I trust these guys and am happy to work with them.”

— **James** Los Angeles Review

Five stars Google

> “I had a great experience speaking to Jeff about a decision I was making for my own business. The information he provided really helped steer me in the right direction. Great lawyer.”

— **Rodrigo Canido** Los Angeles Review

Five stars Google

> “I would say that NextEra Legal is ahead of their peers, but it's safe to say they don't have any. The team at Next Era are operating on a different level and leaving the stuffy practice of Law behind. They helped me navigate the challenges…”

— **Blake R** Los Angeles Review

Further reading

## More on regulatory compliance.

- [Case study: Built to Scale, Compliant from Day One](https://nexteralegal.com/case-studies/compliance-from-day-one/)
- [Blog: Consumer Protection Laws for Contractors](https://nexteralegal.com/blog/hvac-roofing-consumer-protection/)
- [Guide: Fiduciary Duties of Directors and Officers](https://nexteralegal.com/guides/fiduciary-duties/)

Also worth reading

- [Fractional General Counsel for Highly Regulated Businesses](https://nexteralegal.com/who-we-serve/highly-regulated-industries/)
- [Peptide Clinic Compliance Guide](https://nexteralegal.com/who-we-serve/peptide-and-wellness/)

09 People also ask

## Questions about BPC-157.

### Is BPC-157 FDA-approved?

No.

BPC-157 has not been approved by the FDA for any indication, and there is no commercially available prescription product. Its legal status for clinics and pharmacies therefore turns on compounding rules rather than approval, the question Next Era Legal's BPC-157 article works through.

### Does removal from Category 2 mean pharmacies can compound it?

No: removal is not addition to the Bulks List.

BPC-157's removal from Category 2 does not, by itself, let pharmacies compound it. The removal lifted the negative designation, but adding the peptide to the 503A Bulks List is a separate step that has not been taken, a distinction Next Era Legal draws for clinics and pharmacies.

### Can I buy BPC-157 labeled for research and give it to patients?

No.

BPC-157 sold as research use only cannot lawfully be given to patients. The FDA treats administering RUO peptides to humans as misbranding and as distributing unapproved new drugs, and Next Era Legal's article explains that an RUO label offers no protection for a product marketed or distributed for human use.

### What does an 8-6 PCAC vote mean?

It is an advisory recommendation.

An 8-6 PCAC vote is an advisory recommendation to add BPC-157 to the 503A positive Bulks List, not a change in the law. The rules stay as they are until a final rule is published, which is the milestone Next Era Legal's article points to.

Eight locations, one team Typically replies the same business day

- [Los Angeles Beverly Hills Office (310) 734-4791 Mon–Fri](https://nexteralegal.com/locations/los-angeles/)
- [Orange County Newport Beach Office (949) 209-4184 Mon–Fri](https://nexteralegal.com/locations/orange-county/)
- [San Diego University City Office (619) 323-3445 Mon–Fri](https://nexteralegal.com/locations/san-diego/)
- [San Francisco SoMa Office (650) 374-1337 Mon–Fri](https://nexteralegal.com/locations/san-francisco/)
- [Houston Uptown Office (713) 255-2098 Mon–Fri](https://nexteralegal.com/locations/houston/)
- [Metro Detroit Town Center Office (313) 887-4788 Mon–Fri](https://nexteralegal.com/locations/metro-detroit/)
- [Washington, DC K Street Office Phone coming soon Mon–Fri](https://nexteralegal.com/locations/washington-dc/)
- [Miami Brickell Office (305) 686-4866 Mon–Fri](https://nexteralegal.com/locations/miami/)
